---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-24-000151"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:43:08.588169+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q3 revenue $44.8M (+452% YoY); net loss narrows to $41.5M

## Summary
- ZORYVE franchise revenue $44.8M ($22.0M cream 0.3%, $20.3M foam 0.3%, $2.5M cream 0.15%), up 45% QoQ.
- Net loss $41.5M ($0.33/sh) vs $44.8M ($0.73/sh) in Q3 '23; operating cash burn improved 23% QoQ to $34.7M.
- Blended gross-to-net improved to low 50% range from high 50% last quarter; approaching steady state for foam.
- Amended $200M SLR loan: lower rate, maturity extended to Aug '29; prepaid $100M on Oct 8, 2024.
- sNDA for ZORYVE foam in scalp/body psoriasis accepted; PDUFA May 22, 2025. Health Canada approval for foam in SD received.

## SEC filing metadata
- accession: 0001787306-24-000151
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000151/0001787306-24-000151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730624000151/arqt-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-24-000151
- JSON: https://secwatch.observer/filing/0001787306-24-000151.json
- Plain text: https://secwatch.observer/filing/0001787306-24-000151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.